• New class of immuno-oncology drug identified
• Activator of NK cells and CD4+ immune cells
• Potential to boost function of current immuno-oncology drugs.
SYDNEY, April 16, 2019: Noxopharm (ASX:NOX) releases data from the first series of pre-clinical studies confirming that idronoxil (IDX), the active ingredient in the Company’s anti-cancer drug candidate, Veyonda, activates the immune system. The studies confirm that IDX activates cells associated with both the innate and adaptive immune systems, increasing functional natural killer (NK) cells and CD4+ (T-helper) cell numbers. The studies involving human cell and animal test systems are part of a coordinated collaboration between the Company and a number of prominent universities and research institutes in Australia and overseas.
For further information please download PDF attached:
Download this document
